High-Dose Radioactive Stents Do Not Limit Edge Restenosis, Studies Suggest
This article was originally published in The Gray Sheet
Higher-dosed radioactive nonagressive stenting does not significantly reduce edge-stent restenosis rates compared to lower-dosed stents, despite the fact that higher dosed stents significantly reduce in-stent restenosis rates, Remo Albiero, MD, Columbus Hospital, Milan, Italy, told attendees of the American Heart Association scientific sessions Nov. 8 in Atlanta.
You may also be interested in...
Teva plans to begin appeal proceedings, the firm has told Generics Bulletin, after being fined €60.5m ($72m) by the European Commission over an historic “pay-for-delay” arrangement covering subsidiary firm Cephalon’s Provigil (modafinil).
SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.
UK start up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country.